TACX03-GUCY2C / Triumvira - LARVOL DELTA

Functional characterization of GUCY2C-TAC T cells for the treatment of colorectal cancer using preclinical models (SITC 2023) - "Conclusions In vitro and in vivo data confirm strong and specific activity of T cells engineered with humanized GUCY2C-TAC receptors. Taken together, these data support further development of GUCY2C-TAC T cells for therapeutic applications in colorectal cancer."

IO biomarker • Preclinical • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • GUCY2C • HER-2

Triumvira Immunologics to Present New Clinical and Preclinical Data on its TAC-T Cell Technology at SITC 2023 Annual Meeting (PRNewswire) - "Triumvira Immunologics...announced that it will participate with one oral presentation and four posters at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting in San Diego, California, from November 1-5. The company will showcase clinical and preclinical data across various programs, including its ongoing Phase I/II study investigating the safety and efficacy of autologous TAC-T cells targeting human epidermal growth factor receptor 2 (HER2) in relapsed or refractory solid tumors (TACTIC-2 /NCT04727151) and its CLDN18.2, GUCY2C and allogeneic TAC T cell technologies."

P1/2 data • Preclinical • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

Development of GUCY2C-TAC T cells for the treatment of colorectal cancer (SITC 2022) - "Conclusions The in vitro and in vivo data confirm strong and specific activity of GUCY2C-targeted TAC T cells against GUCY2C-expressing tumor models and highlight the versatility of the TAC platform for therapeutic applications in solid tumors. Ethics Approval AUP number 20–10–37, approved by McMaster University’s Animal Research Ethics Board."

IO biomarker • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • CD69 • HER-2

Triumvira Immunologics Demonstrates Strength of Preclinical Research Pipeline for Gastric and Colorectal Cancers in Three Posters at SITC 2022 (Businesswire) - "Triumvira Immunologics...announced preclinical data for its investigational TAC-T cell therapies...at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting....The data demonstrated that the candidate, named GUCY2C-TAC T, effectively eliminates GUCY2C-expressing colorectal cancer cells in vitro. The study also demonstrated that the activation of GUCY2C-TAC T cells was specific to target cells that expressed GUCY2C and that off-target effects were minimal. Additionally, GUCY2C-TAC T cells led to a sustained anti-tumor activity in vivo."

Preclinical • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

Triumvira Immunologics to Present Clinical and Preclinical Updates at Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting (Businesswire) - "Triumvira Immunologics...announced that it will present data from its ongoing clinical and preclinical programs at the upcoming Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, being held Nov. 10-12, 2022, in Boston and virtually. The presentations will include updated clinical data from its Phase 1/2 trial of TAC01-HER2 in patients with solid tumors and preclinical data on T cell therapy candidates TAC01-CLDN18.2 and GUCY2C-TAC T....Building on the proof-of-concept of its clinical-stage autologous TAC01-HER2 program, Triumvira is continuing to develop and advance its gamma delta allogeneic pipeline with IND filings anticipated over the next three years."

P1/2 data • Preclinical • Colorectal Cancer • Gastric Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor